Clinical, Cosmetic and Investigational Dermatology (Jun 2020)
Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults
Abstract
Vidhatha Reddy,1 Bridget Myers,1 Eric J Yang,2 Tina Bhutani1 1University of California, San Francisco, Department of Dermatology, San Francisco, CA, USA; 2Virginia Mason Medical Center, Seattle, WA, USACorrespondence: Vidhatha ReddyUniversity of California, San Francisco, Department of Dermatology, 515 Spruce Street, San Francisco, CA 94118, USAEmail [email protected]: Halobetasol propionate and tazarotene lotion 0.01%/0.045% (HP/TAZ) is a topical medication approved for the treatment of plaque psoriasis in adults. As a treatment modality, HP/TAZ has a combinatory therapeutic effect because it contains both a corticosteroid (HP) and a retinoid (TAZ) component. Here, we review the important clinical efficacy and safety data derived from pivotal clinical trials for HP/TAZ in the treatment of plaque psoriasis. We also discuss the mechanism of action, dosage guidelines, pharmacokinetics/pharmacodynamics, and clinical considerations for HP/TAZ, including why HP/TAZ should be avoided in pregnant patients.Keywords: halobetasol propionate, tazarotene, Duobrii, psoriasis, plaque, topical
